Takeda Pharmaceutical Company Limited (TAK)
Stock Price Chart
Key Info
| Market Cap | 57.80B |
| Revenue (ttm) | 30.89B |
| Net Income (ttm) | 415.19M |
| Shares Out | 3.15B |
| EPS (ttm) | 0.81 |
| PE Ratio | 22.83 |
| Forward PE | 15.08 |
| Dividend | $0.84 |
| Dividend Yield | 4.54% |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $18.49 |
| Previous Close | $18.55 |
| Change ($) | -0.06 |
| Change (%) | -0.32% |
| Day's Open | 18.53 |
| Day's Range | 18.46 - 18.57 |
| Day's Volume | 498,004 |
| 52-Week Range | 12.43 - 20.93 |
More Stats
| Market Cap | 57.80B |
| Enterprise Value | 104.11B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | Mar 30, 2020 |
| Shares Outstanding | 3.15B |
| Float | 3.09B |
| EPS (basic) | n/a |
| EPS (diluted) | 0.81 |
| FCF / Share | 2.18 |
| Dividend | $0.84 |
| Dividend Yield | 4.54% |
| Earnings Yield | 4.38% |
| FCF Yield | 12.70% |
| Payout Ratio | n/a |
| Shares Short | 2.03M |
| Short Ratio | 2.63 |
| Short % of Float | n/a |
| Beta | 1.09 |
| PE Ratio | 22.83 |
| Forward PE | 15.08 |
| P/FCF Ratio | 7.88 |
| PS Ratio | 1.87 |
| PB Ratio | 1.28 |
| Revenue | 30.89B |
| Operating Income | 942.30M |
| Net Income | 415.19M |
| Free Cash Flow | 7.34B |
| Net Cash | -46.31B |
| Net Cash / Share | n/a |
| Gross Margin | 66.89% |
| Operating Margin | 3.05% |
| Profit Margin | 1.30% |
| FCF Margin | 23.76% |
| ROA | 1.45% |
| ROE | 2.50% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | 3,291,188 | 2,097,224 | 1,770,531 | 1,732,051 |
| Revenue Growth | 56.93% | 18.45% | 2.22% | - |
| Gross Profit | 2,201,424 | 1,445,495 | 1,274,610 | 1,173,296 |
| Operating Income | 100,408 | 237,685 | 241,789 | 155,867 |
| Net Income | 44,241 | 135,192 | 186,886 | 114,940 |
| Shares Outstanding | 1,683 | 1,683 | - | - |
| Earnings Per Share | 14.13 | 69.91 | 118.78 | 73.13 |
| EPS Growth | -79.8% | -41.14% | 62.42% | - |
| Dividend Per Share | - | - | 0.81 | 1.19 |
| Dividend Growth | - | - | -32.27% | - |
| Operating Cash Flow | 896,520 | 373,388 | 407,737 | 302,114 |
| Capital Expenditures | -114,504 | -26,960 | -64,040 | -59,031 |
| Free Cash Flow | 782,016 | 346,428 | 343,697 | 243,083 |
| Cash & Equivalents | 653,436 | 725,369 | 375,168 | 0.00 |
| Total Debt | 5,588,139 | 6,038,366 | 1,106,498 | - |
| Net Cash / Debt | -4,934,703 | -5,312,997 | -731,330 | 0.00 |
| Assets | 12,821,094 | 13,792,773 | 4,106,463 | - |
| Liabilities | 8,093,608 | 8,606,782 | 2,089,054 | - |
| Book Value | 4,723,483 | 5,181,985 | 1,997,424 | - |
Company Profile
Company Details
| Full Name | Takeda Pharmaceutical Company Limited |
| Country | Japan |
| Employees | 47,495 |
| CEO | Christophe Weber |
Stock Information
| Ticker Symbol | TAK |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: TAK |
Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.